Technology

Innate Pharma

$4.83
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.31 (+6.76%) Today
$0.00 (0.00%) As of 9:00 PM UTC after-hours

Why Robinhood?

You can watch Innate Pharma and buy or sell other stocks, options, and ETFs commission-free!

About IPHA

Innate Pharma S.A. ADS, also called Innate Pharma, is a biopharmaceutical company. It focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells. The company was founded by Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and François Romagné on September 15, 1999 and is headquartered in Marseille, France. The listed name for IPHA is Innate Pharma S.A. ADS.

CEO
Mondher Mahjoubi
Employees
235
Headquarters
Marseille, Provence-Alpes-Cote-dAzur
Founded
1999
Market Cap
387.80M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
48.28K
High Today
$4.95
Low Today
$4.67
Open Price
$4.91
Volume
36.98K
52 Week High
$8.23
52 Week Low
$3.30

Collections

You May Also Like

SVNLY
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure